Dose intensity
| . | VTD (n = 169) . | VCD (n = 169) . |
|---|---|---|
| Dexamethasone | ||
| 100% of the planned dose | 76.3% | 84.6% |
| Dose reduction | 14.2% | 10.9% |
| Discontinuation | 9.5% | 8.6% |
| Dose intensity | 92.4% | 96.1% |
| Bortezomib | ||
| 100% of the planned dose | 76.9% | 78.1% |
| Dose reduction | 16.0% | 13.6% |
| Discontinuation | 7.1% | 8.3% |
| Dose intensity | 94.9% | 96.4% |
| Thalidomide/cyclophosphamide | ||
| 100% of the planned dose | 62.7% | 71.3% |
| Dose reduction | 21.3% | 16.6% |
| Discontinuation | 16% | 12.1% |
| Dose intensity | 89.9% | 94.5% |
| . | VTD (n = 169) . | VCD (n = 169) . |
|---|---|---|
| Dexamethasone | ||
| 100% of the planned dose | 76.3% | 84.6% |
| Dose reduction | 14.2% | 10.9% |
| Discontinuation | 9.5% | 8.6% |
| Dose intensity | 92.4% | 96.1% |
| Bortezomib | ||
| 100% of the planned dose | 76.9% | 78.1% |
| Dose reduction | 16.0% | 13.6% |
| Discontinuation | 7.1% | 8.3% |
| Dose intensity | 94.9% | 96.4% |
| Thalidomide/cyclophosphamide | ||
| 100% of the planned dose | 62.7% | 71.3% |
| Dose reduction | 21.3% | 16.6% |
| Discontinuation | 16% | 12.1% |
| Dose intensity | 89.9% | 94.5% |